Philips acquires SpectraWAVE

Royal Philips has agreed to acquire SpectraWAVE, Inc., a US-based developer of next-generation coronary intravascular imaging and physiology assessment technologies, to broaden its portfolio of image-guided therapy solutions and distinguish itself from competitors in the interventional cardiology market. The acquisition combines SpectraWAVE’s advanced imaging systems and AI-enabled physiology tools with Philips’ established platforms, seeking to enable more comprehensive clinical insights during percutaneous coronary interventions.

Enhanced Coronary Imaging and Physiology Integration
SpectraWAVE’s core technologies include the HyperVue Imaging System, which integrates Deep Optical Coherence Tomography (DeepOCT) with near-infrared spectroscopy (NIRS) to deliver detailed structural and compositional imaging inside coronary arteries. This Enhanced Vascular Imaging (EVI) approach aims to improve visualization of vessel walls and plaque characteristics beyond what standalone OCT or traditional intravascular imaging modalities can provide, supported by rapid acquisition and automated AI analysis.

In addition, SpectraWAVE’s X1-FFR solution uses AI to derive Fractional Flow Reserve (FFR) from a routine coronary angiogram, enabling physiological assessment of ischemia without requiring a pressure wire. This angio-based FFR capability complements existing physiology tools such as Philips’ OmniWire iFR technology by offering a wire-free option and integrating functional assessment directly into typical workflows.

Strategic Differentiation Within Philips’ Portfolio
The acquisition expands Philips’ intravascular imaging and physiological assessment offerings, which already include Eagle Eye Platinum digital intravascular ultrasound (IVUS) and other modalities, by adding multi-modal imaging and AI-driven functional analysis. Combined with the Azurion image-guided therapy platform—a widely adopted interventional system used globally—the enhanced portfolio aims to provide clinicians with a more comprehensive toolkit for decision-making, procedural guidance, treatment execution and confirmation in a single procedural setting.

Beyond broadening technical capabilities, the integrated ecosystem seeks to differentiate Philips from competitors by unifying structural imaging, compositional data and physiologic metrics with AI support. This approach is positioned to improve the adoption of advanced imaging and physiology tools in everyday practice, targeting workflow efficiency and, ultimately, patient outcomes in the treatment of coronary artery disease, which affects an estimated hundreds of millions of people worldwide.

Market Position and Future Prospects
Financial terms of the transaction were not disclosed. The acquisition aligns with Philips’ broader strategy to invest in minimally invasive, image-guided therapies and deepen the integration of AI across its product portfolio. By incorporating SpectraWAVE’s innovations, Philips aims to reinforce its competitive position in the cardiology segment and respond to growing clinical evidence that advanced imaging and physiological assessment can meaningfully influence procedural success and clinical outcomes.

The combined capabilities are anticipated to support broader clinical adoption of intravascular imaging and physiologic assessment technologies, offering clinicians expanded choice in diagnostic and therapeutic guidance tools and enabling more tailored interventional strategies.

www.philips.com